Global Companion Diagnostic Development Services Market Growth (Status and Outlook) 2026-2032
The global Companion Diagnostic Development Services market size is predicted to grow from US$ 1722 million in 2025 to US$ 3717 million in 2032; it is expected to grow at a CAGR of 11.6% from 2026 to 2032.
Companion diagnostic development services comprise integrated technical, clinical, quality, and regulatory activities provided to pharmaceutical, biotechnology, and diagnostic companies to co-develop an in vitro diagnostic or imaging tool that is essential for the safe and effective use of a corresponding therapy. The service scope covers biomarker strategy, assay selection, reagent and algorithm development, analytical validation, clinical performance studies, clinical trial sample testing, quality-system documentation, global regulatory submissions, technology transfer, commercial deployment, and post-approval change management. Major platforms include next-generation sequencing, PCR and digital PCR, immunohistochemistry and in situ hybridization, flow cytometry, immunoassays, and digital pathology. Programs are generally advanced in parallel with therapeutic development and require coordinated decisions on clinical protocols, specimen strategy, cutoffs, intended use, and regional regulatory pathways. This study focuses on contracted development and validation services supplied to external clients by third-party laboratories, contract research organizations, and diagnostic technology companies, with an estimated blended gross margin of approximately 50%.
Market Trends
Companion diagnostic programs are shifting from single-marker, single-region projects toward multiplex, platform-based, and globally coordinated development. Drug sponsors increasingly engage diagnostic partners during program planning and early clinical development to reduce the risk of late assay replacement, repeat validation, or additional bridging studies. Comprehensive genomic profiling, liquid biopsy, digital pathology, and AI-enabled quantitative scoring are expanding the range of actionable biomarkers, while competition is moving beyond individual assay capabilities toward cross-platform integration, quality systems, global laboratory harmonization, and commercial deployment.
Drivers
Expansion of precision therapeutics, antibody-drug conjugates, immunotherapies, and rare-disease treatments is making patient selection, response prediction, and safety stratification integral to clinical development. Regulatory expectations for coordinated drug and diagnostic development, together with sponsor demand for faster enrollment, shorter timelines, and lower late-stage submission risk, are increasing the use of specialized external partners.
Restraints
Growth is constrained by limited access to high-quality clinical specimens, low biomarker prevalence, cross-border sample restrictions, and the cost of platform changes. Because diagnostic timelines must remain synchronized with the therapeutic program, changes in indication, protocol, specimen type, or cutoff can trigger additional validation, bridging, and submission work, increasing cost and delivery uncertainty.
Opportunities
New demand is emerging in autoimmune, neurodegenerative, infectious, and cell and gene therapy programs beyond oncology. Local laboratory networks for multiregional trials, distributed kit deployment, single-site regulatory pathways followed by broader geographic expansion, and panel-based diagnostics that can add therapeutic claims over time all provide attractive program-extension opportunities.
Challenges
Long-term risks include uncertain clinical utility of novel biomarkers, loss of diagnostic investment when a therapeutic program is discontinued, inconsistent regional requirements, and commercial testing volumes below development expectations. Digital and algorithmic diagnostics must additionally address training-data representativeness, algorithm locking, software change control, laboratory information system integration, and reproducibility across sites.
Value Chain Analysis
Upstream value is supplied by antibodies, primers and probes, sequencing reagents, reference materials, biospecimens, instrument platforms, and bioinformatics tools. Midstream providers combine biomarker science, assay development, clinical laboratory operations, biostatistics, quality management, and regulatory strategy into an evidence package suitable for review. Downstream customers are primarily pharmaceutical and biotechnology companies, with diagnostic companies, central laboratories, and regional laboratory networks supporting commercial deployment. Profitability is strongest where providers control proprietary platforms, sample access, regulatory expertise, and global networks, while routine testing and stand-alone method transfer generally carry weaker pricing power.
Segment Insights
End-to-end co-development typically carries the highest contract value and customer retention because responsibility continues from biomarker confirmation through approval and commercialization. By platform, next-generation sequencing remains a major growth area for multigene and tumor-agnostic programs, immunohistochemistry retains strong demand in antibody-drug conjugates and protein-expression biomarkers, and digital pathology adds value by improving scoring consistency and enabling continuous-variable cutoff development.
Downstream Market Opportunities
Large pharmaceutical companies generally favor partners with global quality systems and commercialization capabilities, while emerging biotechnology companies place greater emphasis on early strategy, flexible development, and capital efficiency. Diagnostic companies and contract research organizations outsource to fill gaps in specialized platforms, clinical specimens, regulatory expertise, or regional laboratory coverage, whereas academic institutions mainly contribute to early biomarker translation and technical validation.
Regional Insights
North America maintains the largest demand base because of its concentration of innovative drug pipelines, established diagnostic companies, and comparatively mature coordinated review mechanisms. Europe has strong molecular and pathology capabilities, although IVDR clinical-evidence requirements and coordination among notified bodies and medicines authorities increase program complexity. Asia-Pacific is expanding rapidly as precision-therapy development, regional trials, and local registration activity grow in China, Japan, and South Korea, creating opportunities in local sample testing and cross-border technology transfer.
Competitive Landscape Analysis
The market includes three principal competitor groups. Global central laboratories and CROs provide integrated development through multiregional trial operations; major diagnostic platform companies use installed instruments, standardized reagents, and regulatory experience to support distributed commercialization; and specialist biomarker laboratories and digital pathology companies differentiate through particular technologies, specimen types, or algorithm development. Sustainable advantage depends on controlling scientific feasibility, timelines, quality systems, regulatory interaction, and post-approval deployment rather than test throughput alone.
Report Scope
LPI (LP Information)' newest research report, the “Companion Diagnostic Development Services Industry Forecast” looks at past sales and reviews total world Companion Diagnostic Development Services sales in 2025, providing a comprehensive analysis by region and market sector of projected Companion Diagnostic Development Services sales for 2026 through 2032. With Companion Diagnostic Development Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Companion Diagnostic Development Services industry.
This Insight Report provides a comprehensive analysis of the global Companion Diagnostic Development Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Companion Diagnostic Development Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Companion Diagnostic Development Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Companion Diagnostic Development Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Companion Diagnostic Development Services.
This report presents a comprehensive overview, market shares, and growth opportunities of Companion Diagnostic Development Services market by product type, application, key players and key regions and countries.
Market Segmentation
Companion diagnostic development services comprise integrated technical, clinical, quality, and regulatory activities provided to pharmaceutical, biotechnology, and diagnostic companies to co-develop an in vitro diagnostic or imaging tool that is essential for the safe and effective use of a corresponding therapy. The service scope covers biomarker strategy, assay selection, reagent and algorithm development, analytical validation, clinical performance studies, clinical trial sample testing, quality-system documentation, global regulatory submissions, technology transfer, commercial deployment, and post-approval change management. Major platforms include next-generation sequencing, PCR and digital PCR, immunohistochemistry and in situ hybridization, flow cytometry, immunoassays, and digital pathology. Programs are generally advanced in parallel with therapeutic development and require coordinated decisions on clinical protocols, specimen strategy, cutoffs, intended use, and regional regulatory pathways. This study focuses on contracted development and validation services supplied to external clients by third-party laboratories, contract research organizations, and diagnostic technology companies, with an estimated blended gross margin of approximately 50%.
Market Trends
Companion diagnostic programs are shifting from single-marker, single-region projects toward multiplex, platform-based, and globally coordinated development. Drug sponsors increasingly engage diagnostic partners during program planning and early clinical development to reduce the risk of late assay replacement, repeat validation, or additional bridging studies. Comprehensive genomic profiling, liquid biopsy, digital pathology, and AI-enabled quantitative scoring are expanding the range of actionable biomarkers, while competition is moving beyond individual assay capabilities toward cross-platform integration, quality systems, global laboratory harmonization, and commercial deployment.
Drivers
Expansion of precision therapeutics, antibody-drug conjugates, immunotherapies, and rare-disease treatments is making patient selection, response prediction, and safety stratification integral to clinical development. Regulatory expectations for coordinated drug and diagnostic development, together with sponsor demand for faster enrollment, shorter timelines, and lower late-stage submission risk, are increasing the use of specialized external partners.
Restraints
Growth is constrained by limited access to high-quality clinical specimens, low biomarker prevalence, cross-border sample restrictions, and the cost of platform changes. Because diagnostic timelines must remain synchronized with the therapeutic program, changes in indication, protocol, specimen type, or cutoff can trigger additional validation, bridging, and submission work, increasing cost and delivery uncertainty.
Opportunities
New demand is emerging in autoimmune, neurodegenerative, infectious, and cell and gene therapy programs beyond oncology. Local laboratory networks for multiregional trials, distributed kit deployment, single-site regulatory pathways followed by broader geographic expansion, and panel-based diagnostics that can add therapeutic claims over time all provide attractive program-extension opportunities.
Challenges
Long-term risks include uncertain clinical utility of novel biomarkers, loss of diagnostic investment when a therapeutic program is discontinued, inconsistent regional requirements, and commercial testing volumes below development expectations. Digital and algorithmic diagnostics must additionally address training-data representativeness, algorithm locking, software change control, laboratory information system integration, and reproducibility across sites.
Value Chain Analysis
Upstream value is supplied by antibodies, primers and probes, sequencing reagents, reference materials, biospecimens, instrument platforms, and bioinformatics tools. Midstream providers combine biomarker science, assay development, clinical laboratory operations, biostatistics, quality management, and regulatory strategy into an evidence package suitable for review. Downstream customers are primarily pharmaceutical and biotechnology companies, with diagnostic companies, central laboratories, and regional laboratory networks supporting commercial deployment. Profitability is strongest where providers control proprietary platforms, sample access, regulatory expertise, and global networks, while routine testing and stand-alone method transfer generally carry weaker pricing power.
Segment Insights
End-to-end co-development typically carries the highest contract value and customer retention because responsibility continues from biomarker confirmation through approval and commercialization. By platform, next-generation sequencing remains a major growth area for multigene and tumor-agnostic programs, immunohistochemistry retains strong demand in antibody-drug conjugates and protein-expression biomarkers, and digital pathology adds value by improving scoring consistency and enabling continuous-variable cutoff development.
Downstream Market Opportunities
Large pharmaceutical companies generally favor partners with global quality systems and commercialization capabilities, while emerging biotechnology companies place greater emphasis on early strategy, flexible development, and capital efficiency. Diagnostic companies and contract research organizations outsource to fill gaps in specialized platforms, clinical specimens, regulatory expertise, or regional laboratory coverage, whereas academic institutions mainly contribute to early biomarker translation and technical validation.
Regional Insights
North America maintains the largest demand base because of its concentration of innovative drug pipelines, established diagnostic companies, and comparatively mature coordinated review mechanisms. Europe has strong molecular and pathology capabilities, although IVDR clinical-evidence requirements and coordination among notified bodies and medicines authorities increase program complexity. Asia-Pacific is expanding rapidly as precision-therapy development, regional trials, and local registration activity grow in China, Japan, and South Korea, creating opportunities in local sample testing and cross-border technology transfer.
Competitive Landscape Analysis
The market includes three principal competitor groups. Global central laboratories and CROs provide integrated development through multiregional trial operations; major diagnostic platform companies use installed instruments, standardized reagents, and regulatory experience to support distributed commercialization; and specialist biomarker laboratories and digital pathology companies differentiate through particular technologies, specimen types, or algorithm development. Sustainable advantage depends on controlling scientific feasibility, timelines, quality systems, regulatory interaction, and post-approval deployment rather than test throughput alone.
Report Scope
LPI (LP Information)' newest research report, the “Companion Diagnostic Development Services Industry Forecast” looks at past sales and reviews total world Companion Diagnostic Development Services sales in 2025, providing a comprehensive analysis by region and market sector of projected Companion Diagnostic Development Services sales for 2026 through 2032. With Companion Diagnostic Development Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Companion Diagnostic Development Services industry.
This Insight Report provides a comprehensive analysis of the global Companion Diagnostic Development Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Companion Diagnostic Development Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Companion Diagnostic Development Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Companion Diagnostic Development Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Companion Diagnostic Development Services.
This report presents a comprehensive overview, market shares, and growth opportunities of Companion Diagnostic Development Services market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
- Next-Generation Sequencing
- PCR and Digital PCR
- Immunohistochemistry and ISH
- Flow Cytometry
- Immunoassays
- Others
Segmentation by Development Stage:
- Discovery and Preclinical
- Early Clinical Development
- Pivotal Clinical Development
- Regulatory Submission
- Commercial Launch
- Post-Approval Lifecycle
Segmentation by Application:
- Pharmaceutical Companies
- Biotechnology Companies
- IVD and Diagnostic Companies
- Academic and Research Institutions
- Others
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Labcorp
- IQVIA Laboratories
- NeoGenomics
- Almac Diagnostic Services
- Precision for Medicine
- Cerba Research
- Eurofins Clinical Diagnostics
- Medpace
- CellCarta
- Foundation Medicine
- Guardant Health
- PathAI
- Geneseeq
- Sysmex Inostics
- Thermo Fisher Scientific
- Agilent Technologies
- Leica Biosystems
- Roche Diagnostics
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Companion Diagnostic Development Services Market Size (2021-2032)
2.1.2 Companion Diagnostic Development Services Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Companion Diagnostic Development Services by Country/Region (2021, 2025 & 2032)
2.2 Companion Diagnostic Development Services Segment by Type
2.2.1 Next-Generation Sequencing
2.2.2 PCR and Digital PCR
2.2.3 Immunohistochemistry and ISH
2.2.4 Flow Cytometry
2.2.5 Immunoassays
2.2.6 Others
2.2.7 Companion Diagnostic Development Services Market Size by Type
2.2.7.1 Companion Diagnostic Development Services Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Companion Diagnostic Development Services Market Size Market Share by Type (2021-2026)
2.3 Companion Diagnostic Development Services Segment by Development Stage
2.3.1 Discovery and Preclinical
2.3.2 Early Clinical Development
2.3.3 Pivotal Clinical Development
2.3.4 Regulatory Submission
2.3.5 Commercial Launch
2.3.6 Post-Approval Lifecycle
2.3.7 Companion Diagnostic Development Services Market Size by Development Stage
2.3.7.1 Companion Diagnostic Development Services Market Size CAGR by Development Stage (2021 VS 2025 VS 2032)
2.3.7.2 Global Companion Diagnostic Development Services Market Size Market Share by Development Stage (2021-2026)
2.4 Companion Diagnostic Development Services Segment by Application
2.4.1 Pharmaceutical Companies
2.4.2 Biotechnology Companies
2.4.3 IVD and Diagnostic Companies
2.4.4 Academic and Research Institutions
2.4.5 Others
2.4.6 Companion Diagnostic Development Services Market Size by Application
2.4.6.1 Companion Diagnostic Development Services Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.4.6.2 Global Companion Diagnostic Development Services Market Size Market Share by Application (2021-2026)
3 COMPANION DIAGNOSTIC DEVELOPMENT SERVICES MARKET SIZE BY PLAYER
3.1 Companion Diagnostic Development Services Market Size Market Share by Player
3.1.1 Global Companion Diagnostic Development Services Revenue by Player (2021-2026)
3.1.2 Global Companion Diagnostic Development Services Revenue Market Share by Player (2021-2026)
3.2 Global Companion Diagnostic Development Services Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 COMPANION DIAGNOSTIC DEVELOPMENT SERVICES BY REGION
4.1 Companion Diagnostic Development Services Market Size by Region (2021-2026)
4.2 Global Companion Diagnostic Development Services Annual Revenue by Country/Region (2021-2026)
4.3 Americas Companion Diagnostic Development Services Market Size Growth (2021-2026)
4.4 APAC Companion Diagnostic Development Services Market Size Growth (2021-2026)
4.5 Europe Companion Diagnostic Development Services Market Size Growth (2021-2026)
4.6 Middle East & Africa Companion Diagnostic Development Services Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Companion Diagnostic Development Services Market Size by Country (2021-2026)
5.2 Americas Companion Diagnostic Development Services Market Size by Type (2021-2026)
5.3 Americas Companion Diagnostic Development Services Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Companion Diagnostic Development Services Market Size by Region (2021-2026)
6.2 APAC Companion Diagnostic Development Services Market Size by Type (2021-2026)
6.3 APAC Companion Diagnostic Development Services Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Companion Diagnostic Development Services Market Size by Country (2021-2026)
7.2 Europe Companion Diagnostic Development Services Market Size by Type (2021-2026)
7.3 Europe Companion Diagnostic Development Services Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Companion Diagnostic Development Services by Region (2021-2026)
8.2 Middle East & Africa Companion Diagnostic Development Services Market Size by Type (2021-2026)
8.3 Middle East & Africa Companion Diagnostic Development Services Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL COMPANION DIAGNOSTIC DEVELOPMENT SERVICES MARKET FORECAST
10.1 Global Companion Diagnostic Development Services Forecast by Region (2027-2032)
10.1.1 Global Companion Diagnostic Development Services Forecast by Region (2027-2032)
10.1.2 Americas Companion Diagnostic Development Services Forecast
10.1.3 APAC Companion Diagnostic Development Services Forecast
10.1.4 Europe Companion Diagnostic Development Services Forecast
10.1.5 Middle East & Africa Companion Diagnostic Development Services Forecast
10.2 Americas Companion Diagnostic Development Services Forecast by Country (2027-2032)
10.2.1 United States Market Companion Diagnostic Development Services Forecast
10.2.2 Canada Market Companion Diagnostic Development Services Forecast
10.2.3 Mexico Market Companion Diagnostic Development Services Forecast
10.2.4 Brazil Market Companion Diagnostic Development Services Forecast
10.3 APAC Companion Diagnostic Development Services Forecast by Region (2027-2032)
10.3.1 China Companion Diagnostic Development Services Market Forecast
10.3.2 Japan Market Companion Diagnostic Development Services Forecast
10.3.3 Korea Market Companion Diagnostic Development Services Forecast
10.3.4 Southeast Asia Market Companion Diagnostic Development Services Forecast
10.3.5 India Market Companion Diagnostic Development Services Forecast
10.3.6 Australia Market Companion Diagnostic Development Services Forecast
10.4 Europe Companion Diagnostic Development Services Forecast by Country (2027-2032)
10.4.1 Germany Market Companion Diagnostic Development Services Forecast
10.4.2 France Market Companion Diagnostic Development Services Forecast
10.4.3 UK Market Companion Diagnostic Development Services Forecast
10.4.4 Italy Market Companion Diagnostic Development Services Forecast
10.4.5 Russia Market Companion Diagnostic Development Services Forecast
10.5 Middle East & Africa Companion Diagnostic Development Services Forecast by Region (2027-2032)
10.5.1 Egypt Market Companion Diagnostic Development Services Forecast
10.5.2 South Africa Market Companion Diagnostic Development Services Forecast
10.5.3 Israel Market Companion Diagnostic Development Services Forecast
10.5.4 Turkey Market Companion Diagnostic Development Services Forecast
10.6 Global Companion Diagnostic Development Services Forecast by Type (2027-2032)
10.7 Global Companion Diagnostic Development Services Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Companion Diagnostic Development Services Forecast
11 KEY PLAYERS ANALYSIS
11.1 Labcorp
11.1.1 Labcorp Company Information
11.1.2 Labcorp Companion Diagnostic Development Services Product Offered
11.1.3 Labcorp Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Labcorp Main Business Overview
11.1.5 Labcorp Latest Developments
11.2 IQVIA Laboratories
11.2.1 IQVIA Laboratories Company Information
11.2.2 IQVIA Laboratories Companion Diagnostic Development Services Product Offered
11.2.3 IQVIA Laboratories Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 IQVIA Laboratories Main Business Overview
11.2.5 IQVIA Laboratories Latest Developments
11.3 NeoGenomics
11.3.1 NeoGenomics Company Information
11.3.2 NeoGenomics Companion Diagnostic Development Services Product Offered
11.3.3 NeoGenomics Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 NeoGenomics Main Business Overview
11.3.5 NeoGenomics Latest Developments
11.4 Almac Diagnostic Services
11.4.1 Almac Diagnostic Services Company Information
11.4.2 Almac Diagnostic Services Companion Diagnostic Development Services Product Offered
11.4.3 Almac Diagnostic Services Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Almac Diagnostic Services Main Business Overview
11.4.5 Almac Diagnostic Services Latest Developments
11.5 Precision for Medicine
11.5.1 Precision for Medicine Company Information
11.5.2 Precision for Medicine Companion Diagnostic Development Services Product Offered
11.5.3 Precision for Medicine Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Precision for Medicine Main Business Overview
11.5.5 Precision for Medicine Latest Developments
11.6 Cerba Research
11.6.1 Cerba Research Company Information
11.6.2 Cerba Research Companion Diagnostic Development Services Product Offered
11.6.3 Cerba Research Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Cerba Research Main Business Overview
11.6.5 Cerba Research Latest Developments
11.7 Eurofins Clinical Diagnostics
11.7.1 Eurofins Clinical Diagnostics Company Information
11.7.2 Eurofins Clinical Diagnostics Companion Diagnostic Development Services Product Offered
11.7.3 Eurofins Clinical Diagnostics Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Eurofins Clinical Diagnostics Main Business Overview
11.7.5 Eurofins Clinical Diagnostics Latest Developments
11.8 Medpace
11.8.1 Medpace Company Information
11.8.2 Medpace Companion Diagnostic Development Services Product Offered
11.8.3 Medpace Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Medpace Main Business Overview
11.8.5 Medpace Latest Developments
11.9 CellCarta
11.9.1 CellCarta Company Information
11.9.2 CellCarta Companion Diagnostic Development Services Product Offered
11.9.3 CellCarta Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 CellCarta Main Business Overview
11.9.5 CellCarta Latest Developments
11.10 Foundation Medicine
11.10.1 Foundation Medicine Company Information
11.10.2 Foundation Medicine Companion Diagnostic Development Services Product Offered
11.10.3 Foundation Medicine Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Foundation Medicine Main Business Overview
11.10.5 Foundation Medicine Latest Developments
11.11 Guardant Health
11.11.1 Guardant Health Company Information
11.11.2 Guardant Health Companion Diagnostic Development Services Product Offered
11.11.3 Guardant Health Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Guardant Health Main Business Overview
11.11.5 Guardant Health Latest Developments
11.12 PathAI
11.12.1 PathAI Company Information
11.12.2 PathAI Companion Diagnostic Development Services Product Offered
11.12.3 PathAI Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 PathAI Main Business Overview
11.12.5 PathAI Latest Developments
11.13 Geneseeq
11.13.1 Geneseeq Company Information
11.13.2 Geneseeq Companion Diagnostic Development Services Product Offered
11.13.3 Geneseeq Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Geneseeq Main Business Overview
11.13.5 Geneseeq Latest Developments
11.14 Sysmex Inostics
11.14.1 Sysmex Inostics Company Information
11.14.2 Sysmex Inostics Companion Diagnostic Development Services Product Offered
11.14.3 Sysmex Inostics Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Sysmex Inostics Main Business Overview
11.14.5 Sysmex Inostics Latest Developments
11.15 Thermo Fisher Scientific
11.15.1 Thermo Fisher Scientific Company Information
11.15.2 Thermo Fisher Scientific Companion Diagnostic Development Services Product Offered
11.15.3 Thermo Fisher Scientific Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Thermo Fisher Scientific Main Business Overview
11.15.5 Thermo Fisher Scientific Latest Developments
11.16 Agilent Technologies
11.16.1 Agilent Technologies Company Information
11.16.2 Agilent Technologies Companion Diagnostic Development Services Product Offered
11.16.3 Agilent Technologies Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Agilent Technologies Main Business Overview
11.16.5 Agilent Technologies Latest Developments
11.17 Leica Biosystems
11.17.1 Leica Biosystems Company Information
11.17.2 Leica Biosystems Companion Diagnostic Development Services Product Offered
11.17.3 Leica Biosystems Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Leica Biosystems Main Business Overview
11.17.5 Leica Biosystems Latest Developments
11.18 Roche Diagnostics
11.18.1 Roche Diagnostics Company Information
11.18.2 Roche Diagnostics Companion Diagnostic Development Services Product Offered
11.18.3 Roche Diagnostics Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Roche Diagnostics Main Business Overview
11.18.5 Roche Diagnostics Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Companion Diagnostic Development Services Market Size (2021-2032)
2.1.2 Companion Diagnostic Development Services Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Companion Diagnostic Development Services by Country/Region (2021, 2025 & 2032)
2.2 Companion Diagnostic Development Services Segment by Type
2.2.1 Next-Generation Sequencing
2.2.2 PCR and Digital PCR
2.2.3 Immunohistochemistry and ISH
2.2.4 Flow Cytometry
2.2.5 Immunoassays
2.2.6 Others
2.2.7 Companion Diagnostic Development Services Market Size by Type
2.2.7.1 Companion Diagnostic Development Services Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Companion Diagnostic Development Services Market Size Market Share by Type (2021-2026)
2.3 Companion Diagnostic Development Services Segment by Development Stage
2.3.1 Discovery and Preclinical
2.3.2 Early Clinical Development
2.3.3 Pivotal Clinical Development
2.3.4 Regulatory Submission
2.3.5 Commercial Launch
2.3.6 Post-Approval Lifecycle
2.3.7 Companion Diagnostic Development Services Market Size by Development Stage
2.3.7.1 Companion Diagnostic Development Services Market Size CAGR by Development Stage (2021 VS 2025 VS 2032)
2.3.7.2 Global Companion Diagnostic Development Services Market Size Market Share by Development Stage (2021-2026)
2.4 Companion Diagnostic Development Services Segment by Application
2.4.1 Pharmaceutical Companies
2.4.2 Biotechnology Companies
2.4.3 IVD and Diagnostic Companies
2.4.4 Academic and Research Institutions
2.4.5 Others
2.4.6 Companion Diagnostic Development Services Market Size by Application
2.4.6.1 Companion Diagnostic Development Services Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.4.6.2 Global Companion Diagnostic Development Services Market Size Market Share by Application (2021-2026)
3 COMPANION DIAGNOSTIC DEVELOPMENT SERVICES MARKET SIZE BY PLAYER
3.1 Companion Diagnostic Development Services Market Size Market Share by Player
3.1.1 Global Companion Diagnostic Development Services Revenue by Player (2021-2026)
3.1.2 Global Companion Diagnostic Development Services Revenue Market Share by Player (2021-2026)
3.2 Global Companion Diagnostic Development Services Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 COMPANION DIAGNOSTIC DEVELOPMENT SERVICES BY REGION
4.1 Companion Diagnostic Development Services Market Size by Region (2021-2026)
4.2 Global Companion Diagnostic Development Services Annual Revenue by Country/Region (2021-2026)
4.3 Americas Companion Diagnostic Development Services Market Size Growth (2021-2026)
4.4 APAC Companion Diagnostic Development Services Market Size Growth (2021-2026)
4.5 Europe Companion Diagnostic Development Services Market Size Growth (2021-2026)
4.6 Middle East & Africa Companion Diagnostic Development Services Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Companion Diagnostic Development Services Market Size by Country (2021-2026)
5.2 Americas Companion Diagnostic Development Services Market Size by Type (2021-2026)
5.3 Americas Companion Diagnostic Development Services Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Companion Diagnostic Development Services Market Size by Region (2021-2026)
6.2 APAC Companion Diagnostic Development Services Market Size by Type (2021-2026)
6.3 APAC Companion Diagnostic Development Services Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Companion Diagnostic Development Services Market Size by Country (2021-2026)
7.2 Europe Companion Diagnostic Development Services Market Size by Type (2021-2026)
7.3 Europe Companion Diagnostic Development Services Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Companion Diagnostic Development Services by Region (2021-2026)
8.2 Middle East & Africa Companion Diagnostic Development Services Market Size by Type (2021-2026)
8.3 Middle East & Africa Companion Diagnostic Development Services Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL COMPANION DIAGNOSTIC DEVELOPMENT SERVICES MARKET FORECAST
10.1 Global Companion Diagnostic Development Services Forecast by Region (2027-2032)
10.1.1 Global Companion Diagnostic Development Services Forecast by Region (2027-2032)
10.1.2 Americas Companion Diagnostic Development Services Forecast
10.1.3 APAC Companion Diagnostic Development Services Forecast
10.1.4 Europe Companion Diagnostic Development Services Forecast
10.1.5 Middle East & Africa Companion Diagnostic Development Services Forecast
10.2 Americas Companion Diagnostic Development Services Forecast by Country (2027-2032)
10.2.1 United States Market Companion Diagnostic Development Services Forecast
10.2.2 Canada Market Companion Diagnostic Development Services Forecast
10.2.3 Mexico Market Companion Diagnostic Development Services Forecast
10.2.4 Brazil Market Companion Diagnostic Development Services Forecast
10.3 APAC Companion Diagnostic Development Services Forecast by Region (2027-2032)
10.3.1 China Companion Diagnostic Development Services Market Forecast
10.3.2 Japan Market Companion Diagnostic Development Services Forecast
10.3.3 Korea Market Companion Diagnostic Development Services Forecast
10.3.4 Southeast Asia Market Companion Diagnostic Development Services Forecast
10.3.5 India Market Companion Diagnostic Development Services Forecast
10.3.6 Australia Market Companion Diagnostic Development Services Forecast
10.4 Europe Companion Diagnostic Development Services Forecast by Country (2027-2032)
10.4.1 Germany Market Companion Diagnostic Development Services Forecast
10.4.2 France Market Companion Diagnostic Development Services Forecast
10.4.3 UK Market Companion Diagnostic Development Services Forecast
10.4.4 Italy Market Companion Diagnostic Development Services Forecast
10.4.5 Russia Market Companion Diagnostic Development Services Forecast
10.5 Middle East & Africa Companion Diagnostic Development Services Forecast by Region (2027-2032)
10.5.1 Egypt Market Companion Diagnostic Development Services Forecast
10.5.2 South Africa Market Companion Diagnostic Development Services Forecast
10.5.3 Israel Market Companion Diagnostic Development Services Forecast
10.5.4 Turkey Market Companion Diagnostic Development Services Forecast
10.6 Global Companion Diagnostic Development Services Forecast by Type (2027-2032)
10.7 Global Companion Diagnostic Development Services Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Companion Diagnostic Development Services Forecast
11 KEY PLAYERS ANALYSIS
11.1 Labcorp
11.1.1 Labcorp Company Information
11.1.2 Labcorp Companion Diagnostic Development Services Product Offered
11.1.3 Labcorp Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Labcorp Main Business Overview
11.1.5 Labcorp Latest Developments
11.2 IQVIA Laboratories
11.2.1 IQVIA Laboratories Company Information
11.2.2 IQVIA Laboratories Companion Diagnostic Development Services Product Offered
11.2.3 IQVIA Laboratories Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 IQVIA Laboratories Main Business Overview
11.2.5 IQVIA Laboratories Latest Developments
11.3 NeoGenomics
11.3.1 NeoGenomics Company Information
11.3.2 NeoGenomics Companion Diagnostic Development Services Product Offered
11.3.3 NeoGenomics Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 NeoGenomics Main Business Overview
11.3.5 NeoGenomics Latest Developments
11.4 Almac Diagnostic Services
11.4.1 Almac Diagnostic Services Company Information
11.4.2 Almac Diagnostic Services Companion Diagnostic Development Services Product Offered
11.4.3 Almac Diagnostic Services Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Almac Diagnostic Services Main Business Overview
11.4.5 Almac Diagnostic Services Latest Developments
11.5 Precision for Medicine
11.5.1 Precision for Medicine Company Information
11.5.2 Precision for Medicine Companion Diagnostic Development Services Product Offered
11.5.3 Precision for Medicine Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Precision for Medicine Main Business Overview
11.5.5 Precision for Medicine Latest Developments
11.6 Cerba Research
11.6.1 Cerba Research Company Information
11.6.2 Cerba Research Companion Diagnostic Development Services Product Offered
11.6.3 Cerba Research Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Cerba Research Main Business Overview
11.6.5 Cerba Research Latest Developments
11.7 Eurofins Clinical Diagnostics
11.7.1 Eurofins Clinical Diagnostics Company Information
11.7.2 Eurofins Clinical Diagnostics Companion Diagnostic Development Services Product Offered
11.7.3 Eurofins Clinical Diagnostics Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Eurofins Clinical Diagnostics Main Business Overview
11.7.5 Eurofins Clinical Diagnostics Latest Developments
11.8 Medpace
11.8.1 Medpace Company Information
11.8.2 Medpace Companion Diagnostic Development Services Product Offered
11.8.3 Medpace Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Medpace Main Business Overview
11.8.5 Medpace Latest Developments
11.9 CellCarta
11.9.1 CellCarta Company Information
11.9.2 CellCarta Companion Diagnostic Development Services Product Offered
11.9.3 CellCarta Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 CellCarta Main Business Overview
11.9.5 CellCarta Latest Developments
11.10 Foundation Medicine
11.10.1 Foundation Medicine Company Information
11.10.2 Foundation Medicine Companion Diagnostic Development Services Product Offered
11.10.3 Foundation Medicine Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Foundation Medicine Main Business Overview
11.10.5 Foundation Medicine Latest Developments
11.11 Guardant Health
11.11.1 Guardant Health Company Information
11.11.2 Guardant Health Companion Diagnostic Development Services Product Offered
11.11.3 Guardant Health Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Guardant Health Main Business Overview
11.11.5 Guardant Health Latest Developments
11.12 PathAI
11.12.1 PathAI Company Information
11.12.2 PathAI Companion Diagnostic Development Services Product Offered
11.12.3 PathAI Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 PathAI Main Business Overview
11.12.5 PathAI Latest Developments
11.13 Geneseeq
11.13.1 Geneseeq Company Information
11.13.2 Geneseeq Companion Diagnostic Development Services Product Offered
11.13.3 Geneseeq Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Geneseeq Main Business Overview
11.13.5 Geneseeq Latest Developments
11.14 Sysmex Inostics
11.14.1 Sysmex Inostics Company Information
11.14.2 Sysmex Inostics Companion Diagnostic Development Services Product Offered
11.14.3 Sysmex Inostics Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Sysmex Inostics Main Business Overview
11.14.5 Sysmex Inostics Latest Developments
11.15 Thermo Fisher Scientific
11.15.1 Thermo Fisher Scientific Company Information
11.15.2 Thermo Fisher Scientific Companion Diagnostic Development Services Product Offered
11.15.3 Thermo Fisher Scientific Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Thermo Fisher Scientific Main Business Overview
11.15.5 Thermo Fisher Scientific Latest Developments
11.16 Agilent Technologies
11.16.1 Agilent Technologies Company Information
11.16.2 Agilent Technologies Companion Diagnostic Development Services Product Offered
11.16.3 Agilent Technologies Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Agilent Technologies Main Business Overview
11.16.5 Agilent Technologies Latest Developments
11.17 Leica Biosystems
11.17.1 Leica Biosystems Company Information
11.17.2 Leica Biosystems Companion Diagnostic Development Services Product Offered
11.17.3 Leica Biosystems Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Leica Biosystems Main Business Overview
11.17.5 Leica Biosystems Latest Developments
11.18 Roche Diagnostics
11.18.1 Roche Diagnostics Company Information
11.18.2 Roche Diagnostics Companion Diagnostic Development Services Product Offered
11.18.3 Roche Diagnostics Companion Diagnostic Development Services Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Roche Diagnostics Main Business Overview
11.18.5 Roche Diagnostics Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Companion Diagnostic Development Services Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Companion Diagnostic Development Services Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Next-Generation Sequencing
Table 4. Major Players of PCR and Digital PCR
Table 5. Major Players of Immunohistochemistry and ISH
Table 6. Major Players of Flow Cytometry
Table 7. Major Players of Immunoassays
Table 8. Major Players of Others
Table 9. Companion Diagnostic Development Services Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Companion Diagnostic Development Services Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Companion Diagnostic Development Services Market Size Market Share by Type (2021-2026)
Table 12. Major Players of Discovery and Preclinical
Table 13. Major Players of Early Clinical Development
Table 14. Major Players of Pivotal Clinical Development
Table 15. Major Players of Regulatory Submission
Table 16. Major Players of Commercial Launch
Table 17. Major Players of Post-Approval Lifecycle
Table 18. Companion Diagnostic Development Services Market Size CAGR by Development Stage (2021 VS 2025 VS 2032) & ($ millions)
Table 19. Global Companion Diagnostic Development Services Market Size by Development Stage (2021-2026) & ($ millions)
Table 20. Global Companion Diagnostic Development Services Market Size Market Share by Development Stage (2021-2026)
Table 21. Companion Diagnostic Development Services Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 22. Global Companion Diagnostic Development Services Market Size by Application (2021-2026) & ($ millions)
Table 23. Global Companion Diagnostic Development Services Market Size Market Share by Application (2021-2026)
Table 24. Global Companion Diagnostic Development Services Revenue by Player (2021-2026) & ($ millions)
Table 25. Global Companion Diagnostic Development Services Revenue Market Share by Player (2021-2026)
Table 26. Companion Diagnostic Development Services Key Players Head office and Products Offered
Table 27. Companion Diagnostic Development Services Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 28. New Products and Potential Entrants
Table 29. Mergers & Acquisitions, Expansion
Table 30. Global Companion Diagnostic Development Services Market Size by Region (2021-2026) & ($ millions)
Table 31. Global Companion Diagnostic Development Services Market Size Market Share by Region (2021-2026)
Table 32. Global Companion Diagnostic Development Services Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Companion Diagnostic Development Services Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Companion Diagnostic Development Services Market Size by Country (2021-2026) & ($ millions)
Table 35. Americas Companion Diagnostic Development Services Market Size Market Share by Country (2021-2026)
Table 36. Americas Companion Diagnostic Development Services Market Size by Type (2021-2026) & ($ millions)
Table 37. Americas Companion Diagnostic Development Services Market Size Market Share by Type (2021-2026)
Table 38. Americas Companion Diagnostic Development Services Market Size by Application (2021-2026) & ($ millions)
Table 39. Americas Companion Diagnostic Development Services Market Size Market Share by Application (2021-2026)
Table 40. APAC Companion Diagnostic Development Services Market Size by Region (2021-2026) & ($ millions)
Table 41. APAC Companion Diagnostic Development Services Market Size Market Share by Region (2021-2026)
Table 42. APAC Companion Diagnostic Development Services Market Size by Type (2021-2026) & ($ millions)
Table 43. APAC Companion Diagnostic Development Services Market Size by Application (2021-2026) & ($ millions)
Table 44. Europe Companion Diagnostic Development Services Market Size by Country (2021-2026) & ($ millions)
Table 45. Europe Companion Diagnostic Development Services Market Size Market Share by Country (2021-2026)
Table 46. Europe Companion Diagnostic Development Services Market Size by Type (2021-2026) & ($ millions)
Table 47. Europe Companion Diagnostic Development Services Market Size by Application (2021-2026) & ($ millions)
Table 48. Middle East & Africa Companion Diagnostic Development Services Market Size by Region (2021-2026) & ($ millions)
Table 49. Middle East & Africa Companion Diagnostic Development Services Market Size by Type (2021-2026) & ($ millions)
Table 50. Middle East & Africa Companion Diagnostic Development Services Market Size by Application (2021-2026) & ($ millions)
Table 51. Key Market Drivers & Growth Opportunities of Companion Diagnostic Development Services
Table 52. Key Market Challenges & Risks of Companion Diagnostic Development Services
Table 53. Key Industry Trends of Companion Diagnostic Development Services
Table 54. Global Companion Diagnostic Development Services Market Size Forecast by Region (2027-2032) & ($ millions)
Table 55. Global Companion Diagnostic Development Services Market Size Market Share Forecast by Region (2027-2032)
Table 56. Global Companion Diagnostic Development Services Market Size Forecast by Type (2027-2032) & ($ millions)
Table 57. Global Companion Diagnostic Development Services Market Size Forecast by Application (2027-2032) & ($ millions)
Table 58. Labcorp Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 59. Labcorp Companion Diagnostic Development Services Product Offered
Table 60. Labcorp Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 61. Labcorp Main Business
Table 62. Labcorp Latest Developments
Table 63. IQVIA Laboratories Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 64. IQVIA Laboratories Companion Diagnostic Development Services Product Offered
Table 65. IQVIA Laboratories Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 66. IQVIA Laboratories Main Business
Table 67. IQVIA Laboratories Latest Developments
Table 68. NeoGenomics Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 69. NeoGenomics Companion Diagnostic Development Services Product Offered
Table 70. NeoGenomics Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 71. NeoGenomics Main Business
Table 72. NeoGenomics Latest Developments
Table 73. Almac Diagnostic Services Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 74. Almac Diagnostic Services Companion Diagnostic Development Services Product Offered
Table 75. Almac Diagnostic Services Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 76. Almac Diagnostic Services Main Business
Table 77. Almac Diagnostic Services Latest Developments
Table 78. Precision for Medicine Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 79. Precision for Medicine Companion Diagnostic Development Services Product Offered
Table 80. Precision for Medicine Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 81. Precision for Medicine Main Business
Table 82. Precision for Medicine Latest Developments
Table 83. Cerba Research Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 84. Cerba Research Companion Diagnostic Development Services Product Offered
Table 85. Cerba Research Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 86. Cerba Research Main Business
Table 87. Cerba Research Latest Developments
Table 88. Eurofins Clinical Diagnostics Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 89. Eurofins Clinical Diagnostics Companion Diagnostic Development Services Product Offered
Table 90. Eurofins Clinical Diagnostics Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 91. Eurofins Clinical Diagnostics Main Business
Table 92. Eurofins Clinical Diagnostics Latest Developments
Table 93. Medpace Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 94. Medpace Companion Diagnostic Development Services Product Offered
Table 95. Medpace Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 96. Medpace Main Business
Table 97. Medpace Latest Developments
Table 98. CellCarta Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 99. CellCarta Companion Diagnostic Development Services Product Offered
Table 100. CellCarta Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 101. CellCarta Main Business
Table 102. CellCarta Latest Developments
Table 103. Foundation Medicine Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 104. Foundation Medicine Companion Diagnostic Development Services Product Offered
Table 105. Foundation Medicine Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 106. Foundation Medicine Main Business
Table 107. Foundation Medicine Latest Developments
Table 108. Guardant Health Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 109. Guardant Health Companion Diagnostic Development Services Product Offered
Table 110. Guardant Health Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 111. Guardant Health Main Business
Table 112. Guardant Health Latest Developments
Table 113. PathAI Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 114. PathAI Companion Diagnostic Development Services Product Offered
Table 115. PathAI Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 116. PathAI Main Business
Table 117. PathAI Latest Developments
Table 118. Geneseeq Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 119. Geneseeq Companion Diagnostic Development Services Product Offered
Table 120. Geneseeq Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 121. Geneseeq Main Business
Table 122. Geneseeq Latest Developments
Table 123. Sysmex Inostics Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 124. Sysmex Inostics Companion Diagnostic Development Services Product Offered
Table 125. Sysmex Inostics Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 126. Sysmex Inostics Main Business
Table 127. Sysmex Inostics Latest Developments
Table 128. Thermo Fisher Scientific Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 129. Thermo Fisher Scientific Companion Diagnostic Development Services Product Offered
Table 130. Thermo Fisher Scientific Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 131. Thermo Fisher Scientific Main Business
Table 132. Thermo Fisher Scientific Latest Developments
Table 133. Agilent Technologies Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 134. Agilent Technologies Companion Diagnostic Development Services Product Offered
Table 135. Agilent Technologies Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 136. Agilent Technologies Main Business
Table 137. Agilent Technologies Latest Developments
Table 138. Leica Biosystems Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 139. Leica Biosystems Companion Diagnostic Development Services Product Offered
Table 140. Leica Biosystems Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 141. Leica Biosystems Main Business
Table 142. Leica Biosystems Latest Developments
Table 143. Roche Diagnostics Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 144. Roche Diagnostics Companion Diagnostic Development Services Product Offered
Table 145. Roche Diagnostics Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 146. Roche Diagnostics Main Business
Table 147. Roche Diagnostics Latest Developments
Table 1. Companion Diagnostic Development Services Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Companion Diagnostic Development Services Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Next-Generation Sequencing
Table 4. Major Players of PCR and Digital PCR
Table 5. Major Players of Immunohistochemistry and ISH
Table 6. Major Players of Flow Cytometry
Table 7. Major Players of Immunoassays
Table 8. Major Players of Others
Table 9. Companion Diagnostic Development Services Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Companion Diagnostic Development Services Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Companion Diagnostic Development Services Market Size Market Share by Type (2021-2026)
Table 12. Major Players of Discovery and Preclinical
Table 13. Major Players of Early Clinical Development
Table 14. Major Players of Pivotal Clinical Development
Table 15. Major Players of Regulatory Submission
Table 16. Major Players of Commercial Launch
Table 17. Major Players of Post-Approval Lifecycle
Table 18. Companion Diagnostic Development Services Market Size CAGR by Development Stage (2021 VS 2025 VS 2032) & ($ millions)
Table 19. Global Companion Diagnostic Development Services Market Size by Development Stage (2021-2026) & ($ millions)
Table 20. Global Companion Diagnostic Development Services Market Size Market Share by Development Stage (2021-2026)
Table 21. Companion Diagnostic Development Services Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 22. Global Companion Diagnostic Development Services Market Size by Application (2021-2026) & ($ millions)
Table 23. Global Companion Diagnostic Development Services Market Size Market Share by Application (2021-2026)
Table 24. Global Companion Diagnostic Development Services Revenue by Player (2021-2026) & ($ millions)
Table 25. Global Companion Diagnostic Development Services Revenue Market Share by Player (2021-2026)
Table 26. Companion Diagnostic Development Services Key Players Head office and Products Offered
Table 27. Companion Diagnostic Development Services Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 28. New Products and Potential Entrants
Table 29. Mergers & Acquisitions, Expansion
Table 30. Global Companion Diagnostic Development Services Market Size by Region (2021-2026) & ($ millions)
Table 31. Global Companion Diagnostic Development Services Market Size Market Share by Region (2021-2026)
Table 32. Global Companion Diagnostic Development Services Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Companion Diagnostic Development Services Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Companion Diagnostic Development Services Market Size by Country (2021-2026) & ($ millions)
Table 35. Americas Companion Diagnostic Development Services Market Size Market Share by Country (2021-2026)
Table 36. Americas Companion Diagnostic Development Services Market Size by Type (2021-2026) & ($ millions)
Table 37. Americas Companion Diagnostic Development Services Market Size Market Share by Type (2021-2026)
Table 38. Americas Companion Diagnostic Development Services Market Size by Application (2021-2026) & ($ millions)
Table 39. Americas Companion Diagnostic Development Services Market Size Market Share by Application (2021-2026)
Table 40. APAC Companion Diagnostic Development Services Market Size by Region (2021-2026) & ($ millions)
Table 41. APAC Companion Diagnostic Development Services Market Size Market Share by Region (2021-2026)
Table 42. APAC Companion Diagnostic Development Services Market Size by Type (2021-2026) & ($ millions)
Table 43. APAC Companion Diagnostic Development Services Market Size by Application (2021-2026) & ($ millions)
Table 44. Europe Companion Diagnostic Development Services Market Size by Country (2021-2026) & ($ millions)
Table 45. Europe Companion Diagnostic Development Services Market Size Market Share by Country (2021-2026)
Table 46. Europe Companion Diagnostic Development Services Market Size by Type (2021-2026) & ($ millions)
Table 47. Europe Companion Diagnostic Development Services Market Size by Application (2021-2026) & ($ millions)
Table 48. Middle East & Africa Companion Diagnostic Development Services Market Size by Region (2021-2026) & ($ millions)
Table 49. Middle East & Africa Companion Diagnostic Development Services Market Size by Type (2021-2026) & ($ millions)
Table 50. Middle East & Africa Companion Diagnostic Development Services Market Size by Application (2021-2026) & ($ millions)
Table 51. Key Market Drivers & Growth Opportunities of Companion Diagnostic Development Services
Table 52. Key Market Challenges & Risks of Companion Diagnostic Development Services
Table 53. Key Industry Trends of Companion Diagnostic Development Services
Table 54. Global Companion Diagnostic Development Services Market Size Forecast by Region (2027-2032) & ($ millions)
Table 55. Global Companion Diagnostic Development Services Market Size Market Share Forecast by Region (2027-2032)
Table 56. Global Companion Diagnostic Development Services Market Size Forecast by Type (2027-2032) & ($ millions)
Table 57. Global Companion Diagnostic Development Services Market Size Forecast by Application (2027-2032) & ($ millions)
Table 58. Labcorp Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 59. Labcorp Companion Diagnostic Development Services Product Offered
Table 60. Labcorp Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 61. Labcorp Main Business
Table 62. Labcorp Latest Developments
Table 63. IQVIA Laboratories Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 64. IQVIA Laboratories Companion Diagnostic Development Services Product Offered
Table 65. IQVIA Laboratories Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 66. IQVIA Laboratories Main Business
Table 67. IQVIA Laboratories Latest Developments
Table 68. NeoGenomics Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 69. NeoGenomics Companion Diagnostic Development Services Product Offered
Table 70. NeoGenomics Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 71. NeoGenomics Main Business
Table 72. NeoGenomics Latest Developments
Table 73. Almac Diagnostic Services Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 74. Almac Diagnostic Services Companion Diagnostic Development Services Product Offered
Table 75. Almac Diagnostic Services Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 76. Almac Diagnostic Services Main Business
Table 77. Almac Diagnostic Services Latest Developments
Table 78. Precision for Medicine Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 79. Precision for Medicine Companion Diagnostic Development Services Product Offered
Table 80. Precision for Medicine Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 81. Precision for Medicine Main Business
Table 82. Precision for Medicine Latest Developments
Table 83. Cerba Research Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 84. Cerba Research Companion Diagnostic Development Services Product Offered
Table 85. Cerba Research Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 86. Cerba Research Main Business
Table 87. Cerba Research Latest Developments
Table 88. Eurofins Clinical Diagnostics Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 89. Eurofins Clinical Diagnostics Companion Diagnostic Development Services Product Offered
Table 90. Eurofins Clinical Diagnostics Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 91. Eurofins Clinical Diagnostics Main Business
Table 92. Eurofins Clinical Diagnostics Latest Developments
Table 93. Medpace Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 94. Medpace Companion Diagnostic Development Services Product Offered
Table 95. Medpace Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 96. Medpace Main Business
Table 97. Medpace Latest Developments
Table 98. CellCarta Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 99. CellCarta Companion Diagnostic Development Services Product Offered
Table 100. CellCarta Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 101. CellCarta Main Business
Table 102. CellCarta Latest Developments
Table 103. Foundation Medicine Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 104. Foundation Medicine Companion Diagnostic Development Services Product Offered
Table 105. Foundation Medicine Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 106. Foundation Medicine Main Business
Table 107. Foundation Medicine Latest Developments
Table 108. Guardant Health Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 109. Guardant Health Companion Diagnostic Development Services Product Offered
Table 110. Guardant Health Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 111. Guardant Health Main Business
Table 112. Guardant Health Latest Developments
Table 113. PathAI Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 114. PathAI Companion Diagnostic Development Services Product Offered
Table 115. PathAI Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 116. PathAI Main Business
Table 117. PathAI Latest Developments
Table 118. Geneseeq Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 119. Geneseeq Companion Diagnostic Development Services Product Offered
Table 120. Geneseeq Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 121. Geneseeq Main Business
Table 122. Geneseeq Latest Developments
Table 123. Sysmex Inostics Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 124. Sysmex Inostics Companion Diagnostic Development Services Product Offered
Table 125. Sysmex Inostics Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 126. Sysmex Inostics Main Business
Table 127. Sysmex Inostics Latest Developments
Table 128. Thermo Fisher Scientific Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 129. Thermo Fisher Scientific Companion Diagnostic Development Services Product Offered
Table 130. Thermo Fisher Scientific Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 131. Thermo Fisher Scientific Main Business
Table 132. Thermo Fisher Scientific Latest Developments
Table 133. Agilent Technologies Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 134. Agilent Technologies Companion Diagnostic Development Services Product Offered
Table 135. Agilent Technologies Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 136. Agilent Technologies Main Business
Table 137. Agilent Technologies Latest Developments
Table 138. Leica Biosystems Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 139. Leica Biosystems Companion Diagnostic Development Services Product Offered
Table 140. Leica Biosystems Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 141. Leica Biosystems Main Business
Table 142. Leica Biosystems Latest Developments
Table 143. Roche Diagnostics Details, Company Type, Companion Diagnostic Development Services Area Served and Its Competitors
Table 144. Roche Diagnostics Companion Diagnostic Development Services Product Offered
Table 145. Roche Diagnostics Companion Diagnostic Development Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 146. Roche Diagnostics Main Business
Table 147. Roche Diagnostics Latest Developments
LIST OF FIGURES
Figure 1. Companion Diagnostic Development Services Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Companion Diagnostic Development Services Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Companion Diagnostic Development Services Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Companion Diagnostic Development Services Sales Market Share by Country/Region (2025)
Figure 8. Companion Diagnostic Development Services Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Companion Diagnostic Development Services Market Size Market Share by Type in 2025
Figure 10. Global Companion Diagnostic Development Services Market Size Market Share by Development Stage in 2025
Figure 11. Companion Diagnostic Development Services in Pharmaceutical Companies
Figure 12. Global Companion Diagnostic Development Services Market: Pharmaceutical Companies (2021-2026) & ($ millions)
Figure 13. Companion Diagnostic Development Services in Biotechnology Companies
Figure 14. Global Companion Diagnostic Development Services Market: Biotechnology Companies (2021-2026) & ($ millions)
Figure 15. Companion Diagnostic Development Services in IVD and Diagnostic Companies
Figure 16. Global Companion Diagnostic Development Services Market: IVD and Diagnostic Companies (2021-2026) & ($ millions)
Figure 17. Companion Diagnostic Development Services in Academic and Research Institutions
Figure 18. Global Companion Diagnostic Development Services Market: Academic and Research Institutions (2021-2026) & ($ millions)
Figure 19. Companion Diagnostic Development Services in Others
Figure 20. Global Companion Diagnostic Development Services Market: Others (2021-2026) & ($ millions)
Figure 21. Global Companion Diagnostic Development Services Market Size Market Share by Application in 2025
Figure 22. Global Companion Diagnostic Development Services Revenue Market Share by Player in 2025
Figure 23. Global Companion Diagnostic Development Services Market Size Market Share by Region (2021-2026)
Figure 24. Americas Companion Diagnostic Development Services Market Size 2021-2026 ($ millions)
Figure 25. APAC Companion Diagnostic Development Services Market Size 2021-2026 ($ millions)
Figure 26. Europe Companion Diagnostic Development Services Market Size 2021-2026 ($ millions)
Figure 27. Middle East & Africa Companion Diagnostic Development Services Market Size 2021-2026 ($ millions)
Figure 28. Americas Companion Diagnostic Development Services Value Market Share by Country in 2025
Figure 29. United States Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 30. Canada Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 31. Mexico Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 32. Brazil Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 33. APAC Companion Diagnostic Development Services Market Size Market Share by Region in 2025
Figure 34. APAC Companion Diagnostic Development Services Market Size Market Share by Type (2021-2026)
Figure 35. APAC Companion Diagnostic Development Services Market Size Market Share by Application (2021-2026)
Figure 36. China Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 37. Japan Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 38. South Korea Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 39. Southeast Asia Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 40. India Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 41. Australia Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 42. Europe Companion Diagnostic Development Services Market Size Market Share by Country in 2025
Figure 43. Europe Companion Diagnostic Development Services Market Size Market Share by Type (2021-2026)
Figure 44. Europe Companion Diagnostic Development Services Market Size Market Share by Application (2021-2026)
Figure 45. Germany Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 46. France Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 47. UK Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 48. Italy Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 49. Russia Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 50. Middle East & Africa Companion Diagnostic Development Services Market Size Market Share by Region (2021-2026)
Figure 51. Middle East & Africa Companion Diagnostic Development Services Market Size Market Share by Type (2021-2026)
Figure 52. Middle East & Africa Companion Diagnostic Development Services Market Size Market Share by Application (2021-2026)
Figure 53. Egypt Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 54. South Africa Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 55. Israel Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 56. Turkey Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 57. GCC Countries Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 58. Americas Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 59. APAC Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 60. Europe Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 61. Middle East & Africa Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 62. United States Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 63. Canada Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 64. Mexico Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 65. Brazil Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 66. China Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 67. Japan Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 68. Korea Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 69. Southeast Asia Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 70. India Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 71. Australia Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 72. Germany Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 73. France Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 74. UK Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 75. Italy Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 76. Russia Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 77. Egypt Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 78. South Africa Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 79. Israel Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 80. Turkey Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 81. Global Companion Diagnostic Development Services Market Size Market Share Forecast by Type (2027-2032)
Figure 82. Global Companion Diagnostic Development Services Market Size Market Share Forecast by Application (2027-2032)
Figure 83. GCC Countries Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 1. Companion Diagnostic Development Services Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Companion Diagnostic Development Services Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Companion Diagnostic Development Services Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Companion Diagnostic Development Services Sales Market Share by Country/Region (2025)
Figure 8. Companion Diagnostic Development Services Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Companion Diagnostic Development Services Market Size Market Share by Type in 2025
Figure 10. Global Companion Diagnostic Development Services Market Size Market Share by Development Stage in 2025
Figure 11. Companion Diagnostic Development Services in Pharmaceutical Companies
Figure 12. Global Companion Diagnostic Development Services Market: Pharmaceutical Companies (2021-2026) & ($ millions)
Figure 13. Companion Diagnostic Development Services in Biotechnology Companies
Figure 14. Global Companion Diagnostic Development Services Market: Biotechnology Companies (2021-2026) & ($ millions)
Figure 15. Companion Diagnostic Development Services in IVD and Diagnostic Companies
Figure 16. Global Companion Diagnostic Development Services Market: IVD and Diagnostic Companies (2021-2026) & ($ millions)
Figure 17. Companion Diagnostic Development Services in Academic and Research Institutions
Figure 18. Global Companion Diagnostic Development Services Market: Academic and Research Institutions (2021-2026) & ($ millions)
Figure 19. Companion Diagnostic Development Services in Others
Figure 20. Global Companion Diagnostic Development Services Market: Others (2021-2026) & ($ millions)
Figure 21. Global Companion Diagnostic Development Services Market Size Market Share by Application in 2025
Figure 22. Global Companion Diagnostic Development Services Revenue Market Share by Player in 2025
Figure 23. Global Companion Diagnostic Development Services Market Size Market Share by Region (2021-2026)
Figure 24. Americas Companion Diagnostic Development Services Market Size 2021-2026 ($ millions)
Figure 25. APAC Companion Diagnostic Development Services Market Size 2021-2026 ($ millions)
Figure 26. Europe Companion Diagnostic Development Services Market Size 2021-2026 ($ millions)
Figure 27. Middle East & Africa Companion Diagnostic Development Services Market Size 2021-2026 ($ millions)
Figure 28. Americas Companion Diagnostic Development Services Value Market Share by Country in 2025
Figure 29. United States Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 30. Canada Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 31. Mexico Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 32. Brazil Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 33. APAC Companion Diagnostic Development Services Market Size Market Share by Region in 2025
Figure 34. APAC Companion Diagnostic Development Services Market Size Market Share by Type (2021-2026)
Figure 35. APAC Companion Diagnostic Development Services Market Size Market Share by Application (2021-2026)
Figure 36. China Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 37. Japan Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 38. South Korea Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 39. Southeast Asia Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 40. India Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 41. Australia Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 42. Europe Companion Diagnostic Development Services Market Size Market Share by Country in 2025
Figure 43. Europe Companion Diagnostic Development Services Market Size Market Share by Type (2021-2026)
Figure 44. Europe Companion Diagnostic Development Services Market Size Market Share by Application (2021-2026)
Figure 45. Germany Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 46. France Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 47. UK Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 48. Italy Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 49. Russia Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 50. Middle East & Africa Companion Diagnostic Development Services Market Size Market Share by Region (2021-2026)
Figure 51. Middle East & Africa Companion Diagnostic Development Services Market Size Market Share by Type (2021-2026)
Figure 52. Middle East & Africa Companion Diagnostic Development Services Market Size Market Share by Application (2021-2026)
Figure 53. Egypt Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 54. South Africa Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 55. Israel Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 56. Turkey Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 57. GCC Countries Companion Diagnostic Development Services Market Size Growth 2021-2026 ($ millions)
Figure 58. Americas Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 59. APAC Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 60. Europe Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 61. Middle East & Africa Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 62. United States Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 63. Canada Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 64. Mexico Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 65. Brazil Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 66. China Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 67. Japan Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 68. Korea Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 69. Southeast Asia Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 70. India Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 71. Australia Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 72. Germany Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 73. France Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 74. UK Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 75. Italy Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 76. Russia Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 77. Egypt Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 78. South Africa Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 79. Israel Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 80. Turkey Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
Figure 81. Global Companion Diagnostic Development Services Market Size Market Share Forecast by Type (2027-2032)
Figure 82. Global Companion Diagnostic Development Services Market Size Market Share Forecast by Application (2027-2032)
Figure 83. GCC Countries Companion Diagnostic Development Services Market Size 2027-2032 ($ millions)
